November 25th 2020, 4:30pm
Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.
November 24th 2020, 12:00pm
The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.
November 23rd 2020, 7:45pm
The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.
November 19th 2020, 6:00pm
Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.
February 9th 2019, 3:28am
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
June 30th 2018, 4:00pm
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.
August 18th 2017, 9:13am
A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
